Exploiting Knowledge on Leishmania Drug Resistance to Support the Quest for New Drugs

New drugs are needed to control leishmaniasis and efforts are currently on-going to counter the neglect of this disease. We discuss here the utility and the impact of associating drug resistance (DR) studies to drug discovery pipelines. We use as paradigm currently used drugs, antimonials and miltef...

Full description

Saved in:
Bibliographic Details
Published inTrends in parasitology Vol. 33; no. 3; pp. 162 - 174
Main Authors Hefnawy, Aya, Berg, Maya, Dujardin, Jean-Claude, De Muylder, Géraldine
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.03.2017
Subjects
Animals
antimonials
Antiprotozoal Agents - pharmacology
Antiprotozoal Agents - therapeutic use
drug development
Drug Discovery
Drug Resistance
Gastroenterology and Hepatology
Humans
Infectious Disease
Leishmania - drug effects
leishmaniasis
Leishmaniasis - drug therapy
miltefosine
drug development
drug resistance
miltefosine
leishmaniasis
antimonials
Online AccessGet full text

Cover

More Information
Summary:New drugs are needed to control leishmaniasis and efforts are currently on-going to counter the neglect of this disease. We discuss here the utility and the impact of associating drug resistance (DR) studies to drug discovery pipelines. We use as paradigm currently used drugs, antimonials and miltefosine, and complement our reflection by interviewing three experts in the field. We suggest DR studies to be involved at two different stages of drug development: (i) the efficiency of novel compounds should be confirmed on sets of strains including recent clinical isolates with DR; (ii) experimental DR should be generated to promising compounds at an early stage of their development, to further optimize them and monitor clinical trials.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1471-4922
1471-5007
DOI:10.1016/j.pt.2016.11.003